LivaNova PLC LivaNova PLC: Transaction in Own Shares
November 15 2016 - 12:00PM
UK Regulatory
TIDMLIVN
15 November 2016
TRANSACTION IN OWN SHARES
LivaNova PLC (the "Company" or "LivaNova") announces that on 15
November 2016, the Board of Directors of LivaNova PLC ("LivaNova"
or the "Company") approved an amendment (the "Amended Share
Repurchase Programme") to the share repurchase programme previously
approved by the Board of Directors on 1 August 2016 (the "Share
Repurchase Programme"). The Share Repurchase Programme had
authorised the Company to repurchase up to $30 million of the
Company's ordinary shares from 1 September 2016 through 31 December
2016 (with further repurchases in each of 2017 and 2018.) The
Amended Share Repurchase Programme authorises the Company to
repurchase up to $50 million of the Company's ordinary shares
through 31 December 2016 (instead of the originally authorised $30
million.) The Amended Share Repurchase Programme is in accordance
with an authority approved by the Company's shareholders at its
annual general meeting on 15 June 2016. Purchases of the ordinary
shares under the Amended Share Repurchase Programme will be carried
out on NASDAQ and will be notified to the market through a UK
Regulatory Information Service on the business day following the
calendar day on which the repurchase occurred. Ordinary shares
repurchased by the Company through the Amended Share Repurchase
Programme will be cancelled. Until further notice, the Amended
Share Repurchase Programme will be conducted pursuant to Rule
10b5-1 under the U.S. Securities Exchange Act and may therefore
continue during closed periods in accordance with applicable
restrictions.
About LivaNova
LivaNova PLC is a global medical technology company formed by
the merger of Sorin S.p.A, a leader in the treatment of
cardiovascular diseases, and Cyberonics Inc., a medical device
company with core expertise in neuromodulation. LivaNova transforms
medical innovation into meaningful solutions for the benefit of
patients, healthcare professionals, and healthcare systems. The
Company employs approximately 4,600 employees worldwide and is
headquartered in London, U.K. With a presence in more than 100
countries, LivaNova operates as three business units: Cardiac
Surgery, Cardiac Rhythm Management, and Neuromodulation, with
operating headquarters in Clamart (France), Mirandola (Italy) and
Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of
the UK's Financial Conduct Authority and traded on London Stock
Exchange (LSE) under the ticker symbol "LIVN".
For more information, please visit www.livanova.com, or
contact:
Investor Relations and Media
Karen King
Vice President, Investor Relations & Corporate
Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications@livanova.com
View source version on businesswire.com:
http://www.businesswire.com/news/home/20161115006250/en/
This information is provided by Business Wire
(END) Dow Jones Newswires
November 15, 2016 12:00 ET (17:00 GMT)
Livanova (LSE:LIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Livanova (LSE:LIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024